Financing - December 6, 2021
Omnio raises 5.5 million SEK
The company has successfully raised 5.5 million SEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers, the company states. “We are delighted with the response […]
In a new job - August 1, 2021
Omnio appoints new CEO
Omnio has appointed Ulrika Norin, who has a long history of working with drug development startups, as its new CEO. “I am excited look forward to being a part of Omnio’s team. We have made significant progress in finding identifying ways to help difficulthard-to-treat heal patients with their chronic wounds. Our work feels rewarding and […]
Financing - May 23, 2019
Omnio receives funding from Swelife innovation programme
Omnio has developed a drug candidate based on the protein plasminogen that can counteract tooth loss. Thanks to the funding the company may now move forward even faster, states the CEO, Patric Stafshede Tooth loss Tooth loss can be caused by periodontitis, an infectious disease that causes teeth to slowly loosen by weakening the jawbone. […]
